MX2022013938A - Etiquetas peptidicas y parejas de union. - Google Patents

Etiquetas peptidicas y parejas de union.

Info

Publication number
MX2022013938A
MX2022013938A MX2022013938A MX2022013938A MX2022013938A MX 2022013938 A MX2022013938 A MX 2022013938A MX 2022013938 A MX2022013938 A MX 2022013938A MX 2022013938 A MX2022013938 A MX 2022013938A MX 2022013938 A MX2022013938 A MX 2022013938A
Authority
MX
Mexico
Prior art keywords
binding partners
peptide tags
peptide
tags
pairs
Prior art date
Application number
MX2022013938A
Other languages
English (en)
Spanish (es)
Inventor
Cyrielle Elyette Fougeroux
Adam Frederik Sander Bertelsen
Susan Thrane
Original Assignee
Adaptvac Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adaptvac Aps filed Critical Adaptvac Aps
Publication of MX2022013938A publication Critical patent/MX2022013938A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
MX2022013938A 2020-05-07 2021-05-07 Etiquetas peptidicas y parejas de union. MX2022013938A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20173377 2020-05-07
PCT/EP2021/062113 WO2021224451A1 (en) 2020-05-07 2021-05-07 Peptide tags and binding partners

Publications (1)

Publication Number Publication Date
MX2022013938A true MX2022013938A (es) 2022-11-30

Family

ID=70613720

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013938A MX2022013938A (es) 2020-05-07 2021-05-07 Etiquetas peptidicas y parejas de union.

Country Status (11)

Country Link
US (1) US20230321260A1 (enExample)
EP (1) EP4146675A1 (enExample)
JP (2) JP7843245B2 (enExample)
KR (1) KR20230006473A (enExample)
CN (1) CN115698045A (enExample)
AU (1) AU2021268757B2 (enExample)
BR (1) BR112022019632A2 (enExample)
CA (1) CA3177709A1 (enExample)
IL (1) IL297111A (enExample)
MX (1) MX2022013938A (enExample)
WO (1) WO2021224451A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016207099C1 (en) 2015-01-15 2021-02-04 University Of Copenhagen Virus-like particle with efficient epitope display
WO2022229817A1 (en) * 2021-04-28 2022-11-03 Bavarian Nordic A/S Vaccines comprising virus-like particles displaying sars-cov-2 antigens and methods of use
US20240240203A1 (en) 2021-05-04 2024-07-18 SpyBiotech Limited Adenoviral vectors and vaccines thereof
WO2024068265A2 (en) 2022-09-30 2024-04-04 Bavarian Nordic A/S Virus-like particles displaying sars-cov-2 antigens as booster vaccines and uses thereof
CN116165377A (zh) * 2023-04-21 2023-05-26 常州伯仪生物科技有限公司 一种通过竞争elisa法进行标签蛋白定量的方法
WO2025097030A1 (en) * 2023-11-02 2025-05-08 Oregon State University Virus-like particles displaying neisseria gonorrhoeae antigens and use thereof for immunization against gonorrhea
GB202317925D0 (en) 2023-11-23 2024-01-10 Spybiotech Ltd Vaccines
CN117723749B (zh) * 2024-02-07 2024-06-04 南昌大学 基于分子粘合剂的动态光散射免疫传感检测方法
WO2026039325A2 (en) 2024-08-12 2026-02-19 Regeneron Pharmaceuticals, Inc. Modified mtm1 genes and uses thereof
WO2026119880A1 (en) * 2024-12-02 2026-06-11 Adaptvac Aps Vaccine for inducing antibodies to inhibit thymic stromal lymphopoietin
WO2026119878A1 (en) * 2024-12-02 2026-06-11 Adaptvac Aps Vaccine for inducing antibodies to inhibit native interleukin-11 signaling

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201002362D0 (en) 2010-02-11 2010-03-31 Isis Innovation Peptide tag systems that spontaneously form an irreversible link to protein partners via isopeptide bonds
CA2964119C (en) * 2014-11-03 2022-10-18 Merck Patent Gmbh Soluble intein fusion proteins and methods for purifying biomolecules
AU2016207099C1 (en) 2015-01-15 2021-02-04 University Of Copenhagen Virus-like particle with efficient epitope display
GB201509782D0 (en) * 2015-06-05 2015-07-22 Isis Innovation Methods and products for fusion protein synthesis
US11807671B2 (en) * 2016-11-16 2023-11-07 Auckland Uniservices Limited Methods for protein ligation and uses thereof
CN111073925B (zh) * 2018-10-19 2022-04-26 北京大学 一种基于无序蛋白偶联酶的高效多肽-多肽偶联系统和方法

Also Published As

Publication number Publication date
EP4146675A1 (en) 2023-03-15
KR20230006473A (ko) 2023-01-10
AU2021268757A1 (en) 2022-12-08
BR112022019632A2 (pt) 2023-10-03
AU2021268757B2 (en) 2026-07-09
CN115698045A (zh) 2023-02-03
CA3177709A1 (en) 2021-11-11
JP2026048917A (ja) 2026-03-17
WO2021224451A1 (en) 2021-11-11
JP7843245B2 (ja) 2026-04-09
JP2023525752A (ja) 2023-06-19
IL297111A (en) 2022-12-01
US20230321260A1 (en) 2023-10-12
WO2021224451A9 (en) 2022-05-27

Similar Documents

Publication Publication Date Title
BR112022019632A2 (pt) Marcadores peptídicos e parceiros de ligação
PH12020551997A1 (en) Psma binding agents and uses thereof
MX2023014458A (es) Anticuerpos anti-ccr8 y usos de los mismos.
PH12019502283A1 (en) Anti-lag3 antibodies
MX2021001841A (es) Anticuerpos anti-gdf15, composiciones y metodos de uso.
MX2021014441A (es) Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
PH12018500906B1 (en) Antibodies specifically binding pd-1 and their uses
PH12018500657A1 (en) Optimized variants of anti-vegf antibodies
MX2019012431A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
MX2022012749A (es) Moleculas de union a linfopoyetina estromal timica (tslp) y metodos de uso de las moleculas.
MX2019012953A (es) Anticuerpo biespecifico contra ox40 y ctla-4.
MY198059A (en) Anti-ox40 antibodies and their uses
AU2016320748A8 (en) Thymic stromal lymphopoietin (TSLP)-binding antibodies and methods of using the antibodies
SG162687A1 (en) Caustic stable chromatography ligands
ZA202309516B (en) Anti-ccr8 antibodies
MX2021006515A (es) Composiciones de methylobacterium para mejorar el rendimiento del maíz.
EP3543335A3 (en) Soluble intein fusion proteins and methods for purifying biomolecules
PH12021551422A1 (en) Anti-il-36 antibodies and methods of use thereof
MX2021000287A (es) Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente.
MX2021004467A (es) Productos lacteos filtrados acidos reducidos en carbohidratos.
MX2024000932A (es) Composiciones que comprenden constituyentes, derivados o extractos de cannabis.
WO2020186090A3 (en) Activatable specific binding member complexes, and methods of making and using same
MX2024000933A (es) Composiciones que comprenden constituyentes, derivados o extracto de cannabis.
MX2021000280A (es) Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente.
MX2019005933A (es) Polipeptidos biespecificos para gitr y ctla-4.